CN Patent

CN115433183B — Kras抑制剂及其用途

Assigned to Risen Suzhou Pharma Tech Co Ltd · Expires 2024-01-02 · 2y expired

What this patent protects

本发明涉及KRAS抑制剂及其用途。具体地，本发明涉及式(I)化合物或其药学上可接受的盐或酯或水合物或立体异构体，包括其的药物组合物，以及上述化合物或组合物在制备用于治疗、抑制或预防KRAS变异诱导疾病的药物中的用途。

USPTO Abstract

本发明涉及KRAS抑制剂及其用途。具体地，本发明涉及式(I)化合物或其药学上可接受的盐或酯或水合物或立体异构体，包括其的药物组合物，以及上述化合物或组合物在制备用于治疗、抑制或预防KRAS变异诱导疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN115433183B
Jurisdiction
CN
Classification
—
Expires
2024-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Risen Suzhou Pharma Tech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.